Host/pathogen interactions at mucosal surfaces: Immune consequences

Research in Microbiology

Volumn 153, Issue 7, 2002, Pages 455-459

  Clare, Simon ^a   Huett, Alan ^a   Dougan, Gordon ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Citrobacter rodentium; Enterotoxin; Infection; Mucosal adjuvant

Indexed keywords

CHOLERA TOXIN; ESCHERICHIA COLI ENTEROTOXIN; GAMMA INTERFERON; INTERLEUKIN 12; NITRIC OXIDE SYNTHASE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

BACTERIAL COLONIZATION; BACTERIAL INFECTION; CITROBACTER; CITROBACTER RODENTIUM; CONFERENCE PAPER; CYTOKINE PRODUCTION; DRUG ACTIVITY; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNIZATION; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; SALMONELLA TYPHIMURIUM; SEQUENCE HOMOLOGY; T LYMPHOCYTE;

ANIMALS; CITROBACTER FREUNDII; DISEASE MODELS, ANIMAL; ENTEROBACTERIACEAE INFECTIONS; HUMANS; IMMUNITY, MUCOSAL; MICE; MUCOUS MEMBRANE;

BACTERIA (MICROORGANISMS); CITROBACTER; CITROBACTER RODENTIUM;

EID: 0036034309     PISSN: 09232508     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0923-2508(02)01345-1     Document Type: Conference Paper

References (35)

1. Agnholt J., Kaltoft K. Infliximab downregulates interferon-gamma production in activated gut T-lymphocytes from patients with Crohn's disease. Cytokine. 15:2001;212-222.
2. Agren L.C., Ekman L., Lowenalder B., Lycke N.Y. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. J. Immunol. 158:1997;3936-3946.
3. Aizapurua D.H., Russell-Jones H. Oral vaccination: Identification of classes of proteins that provoke an immune response upon oral feeding. J. Exp. Med. 167:1988;440-451.
4. Barthold S.W. Diagnostic exercise. Transmissible murine colonic hyperplasia. Lab. Anim. Sci. 4:1980;641-642.
5. Cario E., Podolsky D.K. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect. Immun. 68:2000;7010-7017.
6. Cropley I., Douce G., Roberts M., Chatfield S.N., Pizza M., Marsili I., Rappuoli R., Dougan G. Mucosal and systemic immunogenicity of a recombinant, non-ADP-ribosylating pertussis toxin: Effects of formaldehyde treatment. Vaccine. 13:1995;1643-1648.
7. Cohen R.D. Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience. Inflamm. Bowel Dis. 1:(Suppl. 1):2001;17-22.
8. Czerkinsky C., Anjuere F., McGhee J.R., George-Chandy A., Holmgren J., Kieny M.-P., Fujiyashi K., Mestecky J.F., Pierrefite-Carle V., Rask C., Sun J.B. Mucosal immunity and tolerance: Relevance to vaccine development. Immunol. Rev. 170:1999;197-222.
9. Deng W., Li Y., Vallance B.A., Finlay B.B. Locus of enterocyte effacement from Citrobacter rodentium: Sequence analysis and evidence for horizontal transfer among attaching and effacing pathogens. Infect. Immun. 69:2001;6323-6335.
10. Douce G., Fontana M., Pizza M., Rappuoli R., Dougan G. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Infect. Immun. 65:1997;2821-2828.
11. Douce G., Turcotte C., Cropley I., Roberts M., Pizza M., Domenghini M., Rappuoli R., Dougan G. Mutants of Escherichia coli heat-labile toxin that lack ADP-ribosyltransferase activity act as nontoxic mucosal adjuvants. Proc. Natl. Acad. Sci. USA. 92:1995;16644-16648.
12. Giuliani M.M., Del Giudice G., Giannelli V., Dougan G., Douce G., Rappuoli R., Pizza M. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP- ribosyltransferase activity. J. Exp. Med. 187:1998;1123-1132.
13. Goncalves N.S., Ghaem-Maghami M., Monteleone G., Frankel G., Dougan G., Lewis D.J.M., Simmons C.P., MacDonald T.T. Critical role for tumor necrosis factor alpha in controlling the number of lumenal pathogenic bacteria and immunopathology of infectious colitis. Infect. Immun. 69:2001;6651-6659.
14. Higgins L.M., Frankel G., Connerton I., Goncalves N.S., Dougan G., McDonald T.T. Role of bacterial intimin in colonic hyperplasia and inflammation. Science. 285:1999;588-591.
15. Higgins L.M., Frankel G., Douce G., Dougan G., MacDonald T.T. Citrobacter rodentium infection in mice elicits a mucosal Th1 cytokine response and lesions similar to murine inflammatory bowel disease. Infect. Immun. 67:1999;3031-3039.
16. Holmgren J., Lonnroth I., Svennerholm A.L. Fixation and inactivation of cholera toxin by GM1 ganglioside. Scand. J. Infect. Dis. 5:1973;77-78.
17. Jakobsen H., Schulz D., Pizza M., Rappuoli R., Jonsdottir I. Intranasal immunisation with pneumococcal polysaccharide conjugate vaccines with nontoxic mutants of Escherichia coli heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infections. Infect. Immun. 67:1999;5892-5897.
18. Levine M.M., Dougan G. Optimism over vaccines administered through mucosal surfaces. Lancet. 351:1998;1375-1376.
19. Luperchio S.A., Schauer D.B. Molecular pathogenesis of Citrobacter rodentium transmissible murine colonic hyperplasia. Microbes Infect. 3:2001;333-340.
20. Mastroeni P., Vazquez-Torres A., Fang F., Xu Y., Khan S., Hormaeche C.E., Dougan G. Antimicrobial actions of the NADPH phagocyte oxidase and inducible nitric oxide synthase in experimental salmonellosis. II Effects on microbial proliferation and host survival in vivo. J. Exp. Med. 192:2000;237-247.
21. McDaniel T.K., Kaper J.B. A cloned pathogenicity island from enteropathogenic Escherichia coli confers the attaching and effacing phenotype on E. coli K-12. Mol. Microbiol. 23:1997;399-407.
22. Medzhitov R. Toll-like receptors and innate immunity. Nature Rev. Immunol. 1:2001;135-145.
23. Nagler-Anderson C. Man the barrier! Strategic defences in the intestinal mucosa. Nature Rev. Immunol. 1:2001;59-67.
24. Naik S., Kelly E.J., Meijer L., Petterson S., Sanderson I.R. Absence of Toll-like receptor 4 explains endotoxin hyporesponsiveness in human intestinal epithelium. J. Pediatr. Gastroenterol. Nutr. 32:2001;449-453.
25. Rappuoli R., Pizza M., Douce G., Dougan G. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunol. Today. 20:1999;493-500.
26. Sandborn W.J., Feagan B.G., Hanauer S.B., Present D.H., Sutherland L.R., Kamm M.A., Wolf D.C., Baker J.P., Hawkey C., Archambault A., Bernstein C.N., Novak C., Heath P.K., Targan S.R. An engineered human antibody to TNF (CDP571) for active Crohn's disease: A randomized double-blind placebo-controlled trial. Gastroenterology. 120:2001;1330-1338.
27. Schauer D.B., Falkow S. The eae gene of Citrobacter freundii biotype 4280 is necessary for colonization in transmissible murine colonic hyperplasia. Infect. Immun. 61:1993;4654-4661.
28. Simmons C.P., Ghaem-Magami M., Petrovska L., Lopes L., Chain B.M., Williams N.A., Dougan G. Immunomodulation using bacterial enterotoxins. Scand. J. Immunol. 53:2001;218-226.
29. Simmons C.P., Goncalves N.S., Ghaem-Maghami M., Bajaj-Elliott M., Clare S., Neves B., Frankel G., Dougan G., MacDonald T.T. Impaired resistance and enhanced pathology during infection with a non-invasive, attaching-effacing enteric bacterial pathogen Citrobacter rodentium, in mice lacking IL-12 or INF γ J. Immunol. 168:2002;1804-1812.
30. Simmons C.P., Hussell T., Sparer T., Walzl G., Openshaw P., Dougan G. Mucosally elicited CD8 T cell responses mediate resistance to Respiritory Syncytial Virus infection independently of IFN γ but contribute to immune-associated weight loss. J. Immunol. 166:2001;1106-1113.
31. Sixma T.K., Kalk K.H., Van Zanten B.A., Dauter Z., Kingma J., Witholt B., Hol W.G.J. Refined structure of Escherichia coli heat-labile enterotoxin, a close relative of cholera toxin. J. Mol. Biol. 230:1993;890-918.
32. Smith P.D., Smythies L.E., Mosteller-Barnum M., Sibley D.A., Russell M.W., Merger M., Sellers M.T., Orenstein J.M., Shimada T., Graham M.F., Kubagawa H. Intestinal macrophages lack CD14 and CD89 and consequently are down-regulated for LPS- and IgA-mediated activities. J. Immunol. 167:2001;2651-2656.
33. Teneberg S., Hirst T.R., Angstrom J., Karlsson K.A. Comparison of the glycolipid-binding specificities of cholera toxin and porcine Escherichia coli heat-labile enterotoxin: Identification of a receptor-active non-ganglioside glycolipid for the heat-labile toxin in infant rabbit small intestine. Glycoconj. J. 11:1994;533-540.
34. Vallance B.A., Deng W., Knodler L.A., Finlay B.B. Mice lacking T and B lymphocytes develop transient colitis and crypt hyperplasia yet suffer impaired bacterial clearance during Citrobacter rodentium infection. Infect. Immun. 70:2002;2070-2081.
35. Van den Broeck W., Cox E., Goddeeris B.M. Induction of immune responses in pigs following oral administration of purified F4 fimbriae. Vaccine. 10:1999;2020-2029.